The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

Similar adverse events as those seen with other GLP-1 receptor agonists were reported. The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov Identifier: NCT05203237).

Running back Cam Akers is returning to Minnesota. The Houston Texans have agreed to trade Akers to the Vikings, the Vikings announced Tuesday night. Minnesota will also get a conditional 2026 ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...